K143741 is an FDA 510(k) clearance for the Lipofina Laser System. Classified as Fat Reducing Low Level Laser within the OLI classification (a category for non-invasive low-level laser body contouring systems), Class II - Special Controls.
Submitted by Yolo Medical, Inc. (Carpenteria, Bc, CA). The FDA issued a Cleared decision on April 24, 2015 after a review of 114 days - within the typical 510(k) review window.
This device falls under the General & Plastic Surgery FDA review panel, regulated under 21 CFR 878.5400 - the FDA general and plastic surgery device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the General & Plastic Surgery review framework, consistent with the majority of Class II 510(k) submissions.
NCT02187237
Completed
Interventional
Industry-sponsored
Safety and Effectiveness of the "YOLO TOUCH" LLLT for Circumference Reduction of the Waistline
A RandomizEd DoUble Blinded Controlled Study to Evaluate the Safety and Effectiveness of the "YOLO TOUCH" Low Level Laser Therapy (LLLT) for Circumference Reduction of he Waistline - REDUCE
| Condition studied |
Reduction of the Waist Circumference |
| Study design |
Single group |
| Eligibility |
All sexes
· 18 Years+
|
| Principal investigator |
Matthew Portz, M.D. |
| Sponsor |
Yolo Medical Inc.
(industry)
|
Started 2013-09-01
→
Primary completion 2013-11-01
→
Completed 2014-01-01
Primary outcome
Reduction of girth measurements for the waistline
Secondary outcome
Complications, device related adverse events during LLLT and device related adverse events post LLLT.
Study completed - no results published.
This trial concluded in 2014 but has not posted
results to ClinicalTrials.gov. Completed studies without public results are common
in industry-sponsored device trials; the data may be referenced in the
510(k) Summary PDF or remain unpublished.
View full study on ClinicalTrials.gov